The integration of liquid biopsy, utilizing techniques such as the Oncomine Pan-Cancer Cell-Free Assay and Cobas® EGFR Mutation Test, provided valuable insights into the genetic landscape of these patients. This evidence concerns the gene EGFR and cancer.